MeiraGTx reports 2022 net loss $129.6M; pipeline advances toward 2024 BLA

MeiraGTx Holdings plc

Net loss of $129.6M ($2.87/share) vs $79.6M in 2021; revenue $15.9M (down from $37.7M on lower milestone payments).
Cash and equivalents $115.5M plus $21M Janssen receivables; expected runway into Q4 2024.
Phase 3 Lumeos trial for botaretigene sparoparvovec (XLRP) enrolling; BLA submission on track for 2024.
AAV-hAQP1 for xerostomia showed 75% symptom improvement; Phase 2 planned Q2 2023.
AAV-GAD for Parkinson's dosing patients; enrollment completion anticipated Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MeiraGTx Holdings plc reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 14, 2023, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001558370-23-003644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.